Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas

Advances in Anatomic Pathology

Volumn 3, Issue 3, 1996, Pages 139-155

  DiGiuseppe, Joseph A ^a   Yeo, Charles J ^b   Hruban, Ralph H ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Adenocarcinoma; Carcinoma; Deleted in colon cancer; K ras; Oncogene; p53; Pancreas; Tumor suppressor gene

Indexed keywords

EID: 0000619592     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-199603030-00001     Document Type: Review

References (102)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
2. Steele GD Jr., Osteen RT, Winchester DP, Murphy GP, Menck HR. Clinical highlights from the National Cancer Data Base: 1994. CA Cancer J Clin 1994;44:71-80.
3. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217:430-8.
4. Delcore R, Thomas JH, Hermreck AS. Pancreaticoduodenectomy for malignant pancreatic and periampullary neoplasms in elderly patients. Am J Surg 1991;162:532-6.
5. Trede M, Schwall G, Saeger HD. Survival after pancreaticoduodenectomy. Ann Surg 1990;211:447-58.
6. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality and survival after the Whipple procedure. Ann Surg 1987;206:358-65.
7. Gordon TA, Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995;221:43-9.
8. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-5.
9. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-73.
10. Trede M. The surgical treatment of pancreatic carcinoma. Surgery 1985;97:28-35.
11. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995;221:721-33.
12. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
13. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-10.
14. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993;29A:698-703.
15. Bosset JF, Pavy JJ, Gillet M, Mantion G, Pelissier E, Schraub S. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study. Radiother Oncol 1992;24:191-4.
16. Jessup JM, Steele G Jr, Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993;128:559-64.
17. Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma: a phase II study. Cancer 1993;72:2124-33.
18. Ishikawa O, Ohigashi H, Imaoka S, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg 1994;129:1075-80.
19. Evans DB, Termuhlen PM, Byrd DR, Ames FC, Ochran TG, Rich TA. Intraoperative radiation therapy following pancreaticoduodenectomy. Ann Surg 1993;218:54-60.
20. Cubilla AL, Fitzgerald PJ. Tumors of the exocrine pancreas. 2nd series, fascicle 19. Washington, D.C.: Armed Forces Institute of Pathology, 1984.
21. Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994;54:2761-4.
22. Cubilla A, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976;36:2690-8.
23. Furukawa T, Chiba R, Kobari M, Matsuno S, Nagura H, Takahashi T. Varying grades of epithelial atypia in the pancreatic ducts of humans. Arch Pathol Lab Med 1994;118:227-34.
24. Kozuka S, Sassa R, Taki T, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979;43:1418-28.
25. Pour PM, Sayed S, Sayed G. Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases. Am J Clin Pathol 1982;77:137-52.
26. Cerny WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992;52:4507-13.
27. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
28. Hruban RH, van der Riet P, Erozan YS, Sidransky D. Molecular biology and the early detection of carcinoma of the bladder; the case of Hubert H. Humphrey. N Engl J Med 1994;330:1276-8.
29. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 1994;77:175-8.
30. Allison DC, Bose KK, Hruban RH, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreaticoduodenectomy. Am Surg 1991;214:648-56.
31. Porschen R, Remy U, Bevers G, Schauseil S, Hengels K, Borchard F. Prognostic significance of DNA ploidy in adenocarcinoma of the pancreas: a flow cytometry study of paraffin-embedded specimens. Cancer 1993;71:3846-50.
32. Böttger TC, Störkel S, Wellek S, Stöckle M, Junginger T. Factors influencing survival after resection of pancreatic cancer: a DNA analysis and a histomorphologic study. Cancer 1994;73:63-73.
33. Herrera MF, van Heerden JA, Katzmann JA, Weiland LH, Nagorney DM, Ilstrup D. Evaluation of DNA nuclear pattern as a prognostic determinant in resected pancreatic ductal adenocarcinoma. Ann Surg 1992;215:120-4.
34. Johansson B, Mandahl N, Heim S, Mertens F, Andrén-Sandberg Å, Mitelman F. Chromosome abnormalities in a pancreatic adenocarcinoma. Cancer Genet Cytogenet 1989;37:209-13.
35. Johansson B, Bardi G, Heim S, et al. Nonrandom chromosomal rearrangements in pancreatic carcinomas. Cancer 1992;69:1674-81.
36. Griffin CA, Hruban RH, Long PP, Morsberger LA, Douna-Issa F, Yeo CJ. Chromosome abnormalities in pancreatic adenocarcinoma. Genes Chromo Cancer 1994;9:93-100.
37. Griffin CA, Hruban RH, Morsberger LA, et al. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 1995;55:2394-9.
38. Hahn SA, Seymour AB, Hoque ATMS, et al. Allelotype of pancreatic adenocarcinoma using a xenograft model. Cancer Res 1995;55:4670-5.
39. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
40. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21.
41. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
42. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
43. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
44. Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503-11.
45. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Surg Pathol 1993;142:1534-43.
46. Casey G, Yamanaka Y, Friess H, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
47. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-60.
48. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
49. Levine AJ, Mormand J, Finley CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
50. Hall PA, Lane DP. p53 in tumour pathology: Can we trust immunohistochemistry? - revisited! [Editorial]. J Pathol 1994;172:1-4.
51. Kalthoff H, Schmiegel W, Roeder C, et al. p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-98.
52. van den Berg FM, Baas IO, Polak MM, Offerhaus GJA. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Surg Pathol 1993;142:381-5.
53. Lee CS, Rush M, Charalambous D, Rode J. Alimentary tract and pancreas: immunohistochemical demonstration of the p53 tumor suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 1993;8:465-9.
54. Zhang SY, Ruggeri B, Agarwal P, et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994;118:150-4.
55. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
56. Boschman C, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994;145:1291-5.
57. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
58. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
59. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-8.
60. Hameed M, Marrero AM, Conlon KC, Brennan MF, Klimstra DS. Expression of p53 nucleophosphoprotein in in situ pancreatic ductal adenocarcinoma: an immunohistochemical analysis of 100 cases. Lab Invest 1994;70:767.
61. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature 1984;312:649-51.
62. Zambetti GP, Olson D, Labow M, Levine AJ. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc Natl Acad Sci USA 1992;89:3952-6.
63. Höhne MW, Halatsch ME, Kahl GF, Weinel RJ. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992;52:2616-9.
64. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994;8:27-32.
65. Neuman WL, Wasylyshyn ML, Jacoby R, et al. Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. Genes Chromo Cancer 1991;3:468-73.
66. Horii A, Nakatsuru S, Miyoshi Y, et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992;52:6696-8.
67. Smith K, Johnson KA, Bryan TM. The APC gene product in normal and tumor cells. Proc Natl Acad Sci USA 1993;90:2846-50.
68. Schutte M, da Costa LT, Hahn SA, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 1995;92:5950-4.
69. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
70. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
71. Smit VTHBM, Boot AJM, Smits AMM, Fleuren GJ, Cornelisse CJ, Bos JL. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82.
72. Mariyama M, Kishi K, Nakamura K, Obata H, Nishimura S. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn J Cancer Res 1989;80:622-6.
73. Grünewald K, Lyons J, Fröhlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41.
74. Nagata Y, Abe M, Motoshima K, Nakayama E, Shiku H. Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Jpn J Cancer Res 1990;81:135-40.
75. Tada M, Yokosuka O, Omata M, Onto M, Isono K. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990;66:930-5.
76. Hruban RH, van Mansfeld ADM, Offerhaus GJA, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
77. Warshaw AL, Castillo CFD. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
78. Topal MD. DNA repair, oncogenes and carcinogenesis. Carcinogenesis 1988;9:691-6.
79. Hruban RH, DiGiuseppe JA, Offerhaus GJA. Author's reply. Am J Pathol 1994;145:1547-50.
80. Tada M, Omata M, Ohto M. Ras gene mutations in intraductal papillary neoplasms of the pancreas. Cancer 1991;67:634-7.
81. Lemoine NR, Jain S, Hughes CM, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-6.
82. DiGiuseppe JA, Hruban RH, Offerhaus GJA, et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994;144:889-95.
83. Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993;53:953-6.
84. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
85. Watanabe H, Sawabu N, Ohta H, et al. Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res 1993;84:961-5.
86. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-3573.
87. Shibata D, Almoguera C, Forrester K, et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990;50:1279-83.
88. Van Laethem J, Vertongen P, Deviere J, et al. Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumors. Gut 1995;36:781-7.
89. Lemoine NR, Hall PA. Growth factors and oncogenes in pancreatic cancer. Bailllere's Clin Gastroenterol 1990;4:815-32.
90. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991;163:111-6.
91. Lemoine NR, Hughes CM, Barton CM, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992;166:7-12.
92. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR. The c-erbB-2 protooncogene in human pancreatic cancer. J Pathol 1990;161:195-200.
93. Satoh K, Sasano H, Shimosegawa T, et al. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer 1993;72:51-6.
94. Day JD, DiGiuseppe JA, Yeo CJ, et al. Immunohistochemical evaluation of HER-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996; in press.
95. Lemoine NR, Lobresco M, Leung H, et al. The erbB-3 gene in human pancreatic cancer. J Pathol 1992;168:269-73.
96. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-7.
97. Ekbom A, McLaughlin JK, Karisson B, et al. Pancreatitis and pancreatic cancer: a population-based study. JNCI 1994;86:625-7.
98. Lynch HT. Genetics and pancreatic cancer. Arch Surg 1994;129:266-8.
99. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-5.
100. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
101. Han H-J, Yanagisawa A, Kato Y, Park J-G, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993;53:5087-9.
102. Yeo CJ, Cameron JL. The pancreas. In: Hardy JD, ed. Hardy's textbook of surgery, 2nd ed. Philadelphia: JB Lippincott, 1988:718.